Portola Unruffled By NICE’s Rejection Of Ondexxya
Executive Summary
Although the health technology assessment institute for England has provisionally recommended against the use of Europe’s first and only approved drug for reversing the effects of factor Xa anticoagulants, Portola believes it may now have the evidence needed to reverse this decision.
You may also be interested in...
Italy: Pharma May Have To Disclose Confidential Info Under New Pricing Rules
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
European CHMP Opinions and MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: